Medical Affairs Scientific Publications and Presentations LasofoxifeneATH-1105 Lasofoxifene Publications November 1, 2024 ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer December 7, 2023 Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial December 7, 2023 Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2 May 12, 2021 Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer July 2, 2020 The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor February 25, 2010 Lasofoxifene in Postmenopausal Women with Osteoporosis Lasofoxifene Presentations No presentations available at this time ATH-1105 Publications January 7, 2026 ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole February 7, 2024 ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS ATH-1105 Presentations January 7, 2026 ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, attenuates TDP-43 pathology in preclinical models of ALS June 17, 2024 ATH-1105, a small- molecule targeting the neurotrophic HGF system, is neuroprotective and prolongs survival in the Prp-TDP43A315T mouse model of ALS
